|
1
|
No authors listed. Systemic treatment of
early breast cancer by hormonal, cytotoxic, or immune therapy. 133
randomized trials involving 31,000 recurrences and 24,000 deaths
among 75,000 women Early Breast Cancer Trialists' Collaborative
Group. Lancet. 339:1–15. 1992.
|
|
2
|
Fisher B, Costantino JP, Redmond CK, et
al: Endometrial cancer in tamoxifen-treated breast cancer patients:
findings from the National Surgical Adjuvant Breast and Bowel
Project (NSABP) B-14. J Natl Cancer Inst. 86:527–537. 1994.
View Article : Google Scholar
|
|
3
|
Fornander T, Rutqvist LE, Cedermark B, et
al: Adjuvant tamoxifen in early breast cancer: occurence of new
primary cancers. Lancet. 1:117–120. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fugh-Berman A and Epstein S: Tamoxifen:
disease prevention or disease substitution? Lancet. 340:1143–1145.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rutqvist LE, Johansson H, Signomklao T,
Johansson U, Fornander T and Wilking N: Adjuvant tamoxifen therapy
for early stage breast cancer and second primary malignancies.
Stockholm Breast Cancer Study Group J Natl Cancer Inst. 87:645–651.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Leeuwen FE, Benraadt J, Coebergh JW,
et al: Risk of endometrial cancer after tamoxifen treatment of
breast cancer. Lancet. 343:448–452. 1994.PubMed/NCBI
|
|
7
|
Jones ME, van Leeuwen FE, Hoogendoorn WE,
et al: Endometrial cancer survival after breast cancer in relation
to tamoxifen treatment: pooled results from three countries. Breast
Cancer Res. 14:R912012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bergman L, Beelen ML, Gallee MP, et al:
Risk and prognosis of endometrial cancer after tamoxifen for breast
cancer. Comprehensive Cancer Centres' ALERT Group Assessment of
Liver and Endometrial cancer risk following Tamoxifen. Lancet.
356:881–887. 2000.PubMed/NCBI
|
|
9
|
Le Donne M, Lentini M, De Meo L, Benedetto
V and Mesiti M: Uterine pathologies in patients undergoing
tamoxifen therapy for breast cancer: ultrasonographic,
hysteroscopic and histological findings. Eur J Gynaecol Oncol.
26:623–626. 2005.
|
|
10
|
Cohen I, Altaras MM, Shapira J, Tepper R,
Rosen DJ, Cordoba M, et al: Time-depedent effect of tamoxifen
therapy on endometrial pathology in asymptomatic postmenopausal
breast cancer patients. Int J Gynecol Pathol. 15:152–157. 1996.
View Article : Google Scholar
|
|
11
|
Dowsett M, Jones A, Johnston SR, et al: In
vivo measurement of aromatase inhibition by letrozole (CGS 20267)
in postmenopausal patients with breast cancer. Clin Cancer Res.
1:1511–1515. 1995.PubMed/NCBI
|
|
12
|
Geisler J, King N, Dowsett M, et al:
Influence of anastrozole (Arimidex), a selective, non-steroidal
aromatase inhibitor, on in vivo aromatisation and plasma oestrogen
levels in postmenopausal women with breast cancer. Br J Cancer.
74:1286–1291. 1996. View Article : Google Scholar
|
|
13
|
Howell A, Cuzick J, Baum M, et al ATAC
Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone
or in Combination) trial after completion of 5 years' adjuvant
treatment for breast cancer. Lancet. 365:60–62. 2005.
|
|
14
|
Boccardo F, Rubagotti A, Puntoni M, et al:
Switching to anastrozole versus continued tamoxifen treatment of
early breast cancer: preliminary results of the Italian Tamoxifen
Anastrozole Trial. J Clin Oncol. 23:5138–5147. 2005. View Article : Google Scholar
|
|
15
|
Duffy S, Jackson TL, Lansdown M, et al
ATAC Trialists' Group: The ATAC (‘Arimidex’, Tamoxifen Alone or in
Combination) adjuvant breast cancer trial: baseline endometrial
sub-protocol data on the effectiveness of transvaginal
ultrasonography and diagnostic hysteroscopy. Hum Reprod.
20:294–301. 2005.
|
|
16
|
Gerber B, Krause A, Reimer T, et al:
Anastrozole versus tamoxifen treatment in postmenopausal women with
endocrine-responsive breast cancer and tamoxifen-induced
endometrial pathology. Clin Cancer Res. 12:1245–1250. 2006.
View Article : Google Scholar
|
|
17
|
Valenzano Menada M, Costantini S, Moioli
M, et al: Evaluation of endometrial thickness in hormone receptor
positive early stage breast cancer postmenopausal women switching
from adjuvant tamoxifen treatment to anastrozole. Breast.
17:631–636. 2008.
|
|
18
|
Markovitch O, Tepper R, Fishman A, et al:
Aromatase inhibitors reverse tamoxifen induced endometrial
ultrasonographic changes in postmenopausal breast cancer patients.
Breast Cancer Res Treat. 101:185–190. 2007. View Article : Google Scholar
|
|
19
|
Morales L, Timmerman D, Neven P, et al:
Third generation aromatase inhibitors may prevent endometrial
growth and reverse tamoxifen-induced uterine changes in
postmenopausal breast cancer patients. Ann Oncol. 16:70–74. 2005.
View Article : Google Scholar
|
|
20
|
Cohen I, Beyth Y, Azaria R, Flex D, Figer
A and Tepper R: Ultrasonographic measurement of endometrial changes
following discontinuation of tamoxifen treatment in postmenopausal
breast cancer patients. BJOG. 107:1083–1087. 2000. View Article : Google Scholar
|
|
21
|
Liedman R, Lindahl B, Andolf E, Willen R,
Ingvar C and Ranstam J: Disaccordance between estimation of
endometrial thickness as measured by transvaginal ultrasound
compared with hysteroscopy and directed biopsy in breast cancer
patients treated with tamoxifen. Anticancer Res. 20:4889–4891.
2000.
|
|
22
|
Fung MF, Reid A, Faught W, et al:
Prospective longitudinal study of ultrasound screening for
endometrial abnormalities in women with breast cancer receiving
tamoxifen. Gynecol Oncol. 91:154–159. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bertelli GF, Valenzano M, Costantini S, et
al: Limited value of sonohysterography for endometrial screening in
asymptomatic, postmenopausal patients treated with tamoxifen.
Gynecol Oncol. 78:275–277. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Develioğlu OH, Omak M, Bilgin T, Esmer A
and Tüfekçi M: The endometrium in asymptomatic breast cancer
patients on tamoxifen: value of transvaginal ultrasonography with
saline infusion and Doppler flow. Gynecol Oncol. 93:328–335.
2004.PubMed/NCBI
|
|
25
|
Giorda G, Crivellari D, Veronesi A, Perin
T, Campagnutta E, Carbone A and Scarabelli C: Comparison of
ultrasonography, hysteroscopy, and biopsy in the diagnosis of
endometrial lesions in postmenopausal tamoxifen-treated patients.
Acta Obstet Gynecol Scand. 81:975–980. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hann LE, Giess CS, Bach AM, Tao Y, Baum HJ
and Barakat RR: Endometrial thickness in tamoxifen-treated
patients: correlation with clinical and pathologic findings. AJR Am
J Roentgenol. 168:657–661. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
No authors listed. Tamoxifen for early
breast cancer: an overview of the randomised trials. Early Breast
Cancer Trialists' Collaborative Group. Lancet. 351:1451–1467.
1998.
|
|
28
|
Mourits MJ, Van der Zee AG, Willemse PH,
Ten Hoor KA, Hollema H and De Vries EG: Discrepancy between
ultrasonography and hysteroscopy and histology of endometrium in
postmenopausal breast cancer patients using tamoxifen. Gynecol
Oncol. 73:21–26. 1999. View Article : Google Scholar
|
|
29
|
Neven P and Vernaeve H: Guidelines for
monitoring patients taking tamoxifen treatment. Drug Saf. 22:1–11.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jordan VC and Assikis VJ: Endometrial
carcinoma and tamoxifen: clearing up a controversy. Clin Cancer
Res. 1:467–472. 1995.PubMed/NCBI
|
|
31
|
Dallenbach-Hellweg G and Hahn U: Mucinous
and clear cell adenocarcinomas of the endometrium in patients
receiving antiestrogens (tamoxifen) and gestagens. Int J Gynecol
Pathol. 14:7–15. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ferguson SE, Olshen AB, Viale A, Awtrey
CS, Barakat RR and Boyd J: Gene expression profiling of
tamoxifen-associated uterine cancers: evidence for two molecular
classes of endometrial carcinoma. Gynecol Oncol. 92:719–725. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wilder JL, Shajahan S, Khattar NH, et al:
Tamoxifen-associated malignant endometrial tumors: pathologic
features and expression of hormone receptors estrogen-alpha,
estrogen-beta and progesterone; a case controlled study. Gynecol
Oncol. 92:553–558. 2004. View Article : Google Scholar
|
|
34
|
Slomovitz BM, Sun CC, Ramirez PT, Bodurka
DC, Diaz P and Lu KH: Does tamoxifen use affect prognosis in breast
cancer patients who develop endometrial cancer? Obstet Gynecol.
104:255–260. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fles R, Hoogendoorn WE, Platteel I, et al:
Genomic profile of endometrial tumors depends on morphological
subtype, not on tamoxifen exposure. Genes Chromosomes Cancer.
49:699–710. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schaapveld M, Visser O, Louwman MJ, et al:
Risk of new primary nonbreast cancers after breast cancer
treatment: a Dutch population-based study. J Clin Oncol.
26:1239–1246. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kirova YM, De Rycke Y, Gambotti L, Pierga
JY, Asselain B and Fourquet A; Institut Curie Breast Cancer Study
Group: Second malignancies after breast cancer: the impact of
different treatment modalities. Br J Cancer. 98:870–874. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kirova YM, Gambotti L, De Rycke Y, Vilcoq
JR, Asselain B and Fourquet A: Risk of second malignancies after
adjuvant radio-therapy for breast cancer: a large-scale, single
institution review. Int J Radiat Oncol Biol Phys. 68:359–363. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Winer EP, Hudis C, Burstein HJ, et al:
American Society of Clinical Oncology technology assessment on the
use of aromatase inhibitors as adjuvant therapy for postmenopausal
women with hormone receptor-positive breast cancer: status report
2004. J Clin Oncol. 23:619–629. 2005. View Article : Google Scholar
|
|
40
|
Machado F, Rodríguez JR, León JP,
Rodríguez JR, Parrilla JJ and Abad L: Tamoxifen and endometrial
cancer. Is screening necessary? A review of the literature. Eur J
Gynaecol Oncol. 26:257–265. 2005.PubMed/NCBI
|
